Smart Life Sciences Manufacturing Market Report 2026

The smart life sciences manufacturing market size has grown rapidly in recent years. It will grow from $28.59 billion in 2025 to $32.83 billion in 2026 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to increasing complexity of life sciences manufacturing processes, rising regulatory scrutiny on product quality, expansion of pharmaceutical and biopharma production capacity, early adoption of automation technologies, growing demand for manufacturing traceability.

The smart life sciences manufacturing market size is expected to see rapid growth in the next few years. It will grow to $59.21 billion in 2030 at a compound annual growth rate (CAGR) of 15.9%. The growth in the forecast period can be attributed to increasing investments in smart pharma factories, rising adoption of digital twin technologies, expansion of personalized medicine manufacturing, growing integration of AI-driven quality analytics, increasing focus on supply chain visibility and resilience. Major trends in the forecast period include increasing adoption of digital manufacturing execution systems, rising integration of iot-enabled production monitoring, growing use of advanced data analytics for process optimization, expansion of automation and robotics in pharma manufacturing, enhanced focus on regulatory compliance and quality control.

Rising demand for personalized medicine is expected to propel the growth of the smart life sciences manufacturing market going forward. Personalized medicine refers to an approach to medical treatment and healthcare that tailors medical decisions, practices, interventions, and therapies to individual patients. Rising demand for personalized medicine is pushing the life sciences industry to adopt smart manufacturing technologies and processes to enable efficient, precise, and flexible production of customized pharmaceuticals and therapies and improve treatment outcomes. For instance, in February 2024, according to Personlaized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the rising demand for personalized medicine is driving the growth of the smart life sciences manufacturing market.

Major market players are concentrating their efforts on creating innovative AI (artificial intelligence) medical technologies to sustain their position in the market. AI-based advancements are needed in smart life science to analyze and interpret vast amounts of data, streamline processes and enable more personalized engagement. For instance, in May 2023, Google Cloud Platform LLC, a US-based technology company, launched two new AI-powered solutions to accelerate drug discovery and precision medicine. This innovative tool can help researchers discover new drugs faster and more efficiently. Additionally, these tools can help improve the accuracy of drug development and reduce the cost of bringing new drugs to market. Moreover, it has the potential to accelerate the growth of new drugs and improve patients' lives.

In March 2024, Ingersoll Rand Inc., a US-based provider of industrial and precision technologies, acquired ILC Dover for approximately US $2.325 billion. Through this acquisition, Ingersoll Rand aims to expand its presence in the life sciences manufacturing market by integrating ILC Dover’s single-use powder and liquid containment solutions and advanced components for biopharmaceutical and medical device production. ILC Dover is a US-based company that provides engineered solutions for biopharma, pharmaceutical, and medical device manufacturing, including single-use containment systems and specialty components.

Major companies operating in the smart life sciences manufacturing market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Novartis AG, Merck and Co Inc, Sanofi S A, GlaxoSmithKline plc, AstraZeneca plc, Bristol Myers Squibb, Eli Lilly and Company, AbbVie Inc, Amgen Inc, Gilead Sciences Inc, Biogen Inc, Takeda Pharmaceutical Company Limited, Bayer AG, Boehringer Ingelheim, Novo Nordisk A S, Teva Pharmaceutical Industries Ltd, CSL Limited.

North America was the largest region in the smart life sciences manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the smart life sciences manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the smart life sciences manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the smart life sciences manufacturing market by increasing costs of imported automation equipment, sensors, control systems, industrial software platforms, and advanced manufacturing hardware. Pharmaceutical and biopharma manufacturers in North America and Europe are most affected due to reliance on imported high-precision equipment, while Asia-Pacific faces higher costs for system exports. These tariffs are increasing capital expenditure and slowing modernization projects. However, they are also encouraging localized manufacturing of automation solutions, regional system integration expertise, and long-term investments in domestic smart manufacturing infrastructure.

The smart life sciences manufacturing market research report is one of a series of new reports that provides smart life sciences manufacturing market statistics, including smart life sciences manufacturing industry global market size, regional shares, competitors with a smart life sciences manufacturing market share, detailed smart life sciences manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the smart life sciences manufacturing industry. This smart life sciences manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Smart life sciences manufacturing employs technology-driven strategies to oversee the production process within the life sciences industry, utilizing Internet-connected equipment. Its purpose is to identify opportunities for automation and enhance industrial performance through data analytics.

The main components of smart life sciences manufacturing are solutions and services. Solutions denote distinct and essential components within a larger system, incorporating various technologies like augmented reality and virtual reality systems, the Internet of Things (IoT), artificial intelligence, cybersecurity, big data, among others. These technologies find applications in pharmaceuticals, biopharmaceuticals, and medical devices.

The smart life sciences manufacturing includes revenues earned by entities by providing services such as process automation and integration, supply chain optimization, bioprocessing solutions, process optimization, digital twin implementation and robotics integration. The market value includes the value of related goods sold by the service provider or included within the service offering. The smart life sciences manufacturing market also includes sales of manufacturing execution systems, robotic systems, laboratory automation equipment, real-time monitoring devices and Internet of Things (IoT) devices that are used in providing smart life sciences manufacturing. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.